This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Verona Pharma 配当と自社株買い
配当金 基準チェック /06
Verona Pharma配当金を支払った記録がありません。
主要情報
n/a
配当利回り
0.1%
バイバック利回り
| 総株主利回り | 0.1% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
Seeking Alpha • Jun 18
Verona Pharma: An Impressive Initial Launch
Summary Verona Pharma's Ohtuvayre launch has driven rapid revenue growth and strong commercial execution, with blockbuster potential and global expansion on the way. Q1 results beat expectations, with surging sales and positive analyst sentiment, but recent insider selling raise some caution about the current valuation. Shares have already doubled in 2025, can the rally continue? An analysis of Verona Pharma follows in the paragraphs below. Read the full article on Seeking Alpha
新しいナラティブ • May 11
Ohtuvayre Launch And EU Approval Will Unlock Future Markets
Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential.Seeking Alpha • Mar 13
Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Summary Verona Pharma plc's Ohtuvayre, approved for COPD, has driven the Pharma's stock up >350%, but intense competition and high valuation prompted a downgrade to “Hold”. Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other established drugs raise concerns. Verona's unique MoA offers expansion opportunities, but the crowded market and potential price wars could hinder growth. With no other products in the pipeline, Verona's future hinges on Ohtuvayre's rapid sales ramp-up and potential new market approvals. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Summary Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad label and significant prescriber uptake suggest potential for higher-than-expected peak annual sales. Verona Pharma holds $336 million in cash, projecting operational funding through at least the end of 2026. Given Ohtuvayre's strong market entry and the unmet needs in COPD treatment, a 'buy' recommendation for VRNA remains warranted, though its valuation seems fully priced. Read the full article on Seeking AlphaSeeking Alpha • Nov 27
Verona Pharma: In COPD, There's A Corner With Their Name On It
Summary Verona Pharma recently got approval for ensifentrine in COPD. Ensifentrine has a differentiated MoA and superior safety profile. Despite a diverse market, Verona will find its own place here. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
Verona Pharma: A Post FDA Approval Analysis
Summary The stock of Verona Pharma has surged following the company's first FDA approval in late June, which was largely expected. The company's newly approved drug is targeting COPD maintenance, which is a massive market. However, there are numerous, well-funded and established players in the market, and more are on the horizon. What's next for Verona now that it has garnered FDA approval for its franchise product? An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 20
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Summary Verona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval. Potential competition from Sanofi / Regeneron's Dupixent poses a threat, but Verona may have a head start in the market thanks to a delay in the PDUFA for Dupixent. Verona's market cap undervalues its potential success, with potential for significant growth and M&A interest. Incumbents in the COPD space include GSK's advair and AstraZeneca's symbicort - this makes the commercial launch of ensifentrine potentially tricky. Nevertheless, the strong safety and efficacy profile and its differentiated MoA mark it out as a potential "blockbuster" drug, which makes a relatively persuasive bull case for Verona stock. Read the full article on Seeking AlphaSeeking Alpha • May 23
Verona Pharma: Key Inflection Point Directly Ahead
Summary Verona Pharma plc stock has lost most of its gains from a strong rally late last year. However, the company has a pivotal FDA decision coming up next month around its primary candidate Ensifentrine. Verona has secured necessary funding to support commercialization, and the analyst firm community is universally positive on the company's prospects. An updated analysis around Verona Pharma follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Feb 15
Verona Pharma: A Few Points From The Bull And Bear Case
Summary VRNA's ensifentrine could be approved for the maintenance treatment of chronic obstructive pulmonary disease in June 2024. VRNA had $257M in cash at the end of Q3'23, and a debt facility worth up to $400M was set up in early 2024. While VRNA has the funding to go it alone in the launch of the ensifentrine, a buyout is still a possibility. Read the full article on Seeking AlphaSeeking Alpha • Jan 19
Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Summary Verona Pharma plc develops respiratory disease medicines, with its lead asset being ensifentrine, an inhaled dual inhibitor of PDE3 and PDE4 enzymes. Ensifentrine is being developed in multiple formulations and is currently under FDA review for the treatment of COPD. Positive phase 3 data showed a reduction in exacerbation rates and improvements in lung function with ensifentrine compared to placebo. Read the full article on Seeking AlphaSeeking Alpha • Sep 13
Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Summary Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrine as maintenance treatment of COPD is expected by end of 2022. The global market opportunity for Chronic Obstructive Pulmonary Disease is expected to reach $14.1 billion by 2025. With ensifentrine activating the Cystic Fibrosis Transmembrane Conductance Regulator, it might be worth exploring as a possible treatment for patients with Cystic Fibrosis. Verona Pharma (NASDAQ:VRNA) is a great speculative biotech play to look into. That's because it already reported positive results from one study using ensifentrine for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). It has a data readout from its second phase 3 study towards the end of 2022, which if also successful, I believe could be a huge value inflection point for this biotech. This drug is unique because it has a dual targeting mechanism of action, allowing it to be different from other currently available therapies. Not only that, but it was noted that patients who received nebulized ensifentrine in the phase 3 ENHANCE-2 study, achieved both the primary and secondary endpoints. On top of that, it was able to reduce exacerbations in patients with COPD by 42% compared to placebo. This was one of the two phase 3 studies evaluating ensifentrine as a nebulized drug. The second phase 3 ENHANCE-1 study is expected to report results by the end of 2022. This would be a major catalyst for investors to look forward to. It is still risky, because there is no guarantee that this second phase 3 study will be successful. Still, the drug did well in one phase 3 study and in a prior phase 2 study, meeting statistical significance in both instances. Patients in these studies were on background therapies which also likely helped. If the second phase 3 study is successful (ENHANCE-1), then the company will be able to file a New Drug Application (NDA) to the FDA for ensifentrine in the 1st half of 2023. There is an opportunity to expand upon the potential territory for which this drug can be marketed as maintenance treatment for COPD. This is because Verona Pharma's partner Nuance received clearance to initiate a phase 1 and phase 3 study, using ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD), in mainland China. Lastly, with the way the drug was developed, it also has the ability to activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). As such, ensifentrine could also be advanced for the treatment of patients with Cystic Fibrosis. With proof of concept established for ensifentrine as a maintenance treatment for COPD, plus the ability to expand its potential towards another market share and indication, these are the reasons why I believe it is a great speculative biotech play to look into. Ensifentrine For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease The main drug in the pipeline is ensifentrine, which is being developed for the treatment of patients with chronic obstructive pulmonary disorder (COPD). But before diving into COPD itself and the positive clinical results from one of the two phase 3 studies, it's important to note the mechanism of action of this drug. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. PDE3 and PDE4 have anti-inflammatory and bronchodilator effects, which both when combined have synergistic properties. This, instead of just using a PDE3 inhibitor or a PDE4 inhibitor alone. There was a challenge though in that prior drugs such as this were developed for oral use (pill form). The problem is that the efficacy was not as great when delivered in such a fashion, plus the side effects. As such, Verona Pharma developed the nebulized version which was explored in the positive phase 3 study. With this type of delivery, the drug could not only work better because it reaches the point of interest quicker but also reduce systemic side effects as well. "Nebulized" means converting a liquid substance like ensifentrine to spray form. Chronic obstructive pulmonary disease is where the airflow of a person is blocked, which in turn makes it hard for them to breathe. You may have heard of chronic bronchitis or gotten it, this is one condition as part of COPD. Another, would be something known as emphysema, which is where the air sacs in the lungs become damaged. It is estimated that there are 3 million cases in the United States alone each year. The global market opportunity for Chronic obstructive pulmonary disease is expected to reach $14.1 billion by 2025. Symptoms that these patients experience are as follows: Chronic coughing Wheezing constantly Shortness of breath I also view this space as an important one. That's because those with COPD have damage caused to the lungs that can't be reversed. Other oral steroids or rescue inhalers can control symptoms and minimize further damage to an extent. However, it's important that new treatments like ensifentrine help to further reduce damage in a more sustained fashion as a long-term treatment option. Once the damage is done to the lungs then there aren't many drugs which can reverse this effect. Moving on to the ENHANCE program itself, this was designed to set up two identical studies, which are set to recruit up to 800 COPD patients in each. Both of these studies are known as ENHANCE-1 and ENHANCE-2. The way that each of these studies were set up is that they treated these patients with nebulized ensifentrine as a monotherapy and then added a bronchodilator (another drug used to expand airway of the lungs) such as LAMA or LABA, and then compare it to placebo. About 20% of patients received another type of therapy to help expand lung airways such as ICS (inhaled corticosteroids). Both of these studies were designed to treat patients over a 24-week period. However, a key difference is that ENHANCE-1 is also evaluating patients for long term safety as well over a 48 week period. Thus, why this phase 3 study is taking a bit longer to complete. As I noted in the beginning of this article, the ENHANCE-2 trial met the primary endpoint and all secondary endpoints as well. What I want to key in on, which is the most important for this drug to ever receive approval would be the primary endpoint. The primary endpoint is improvement in lung function as measured by average Forced Expiration Volume 1 (FEV1) AUC (Area under the curve) 0-12 hours post dose at week 12. It was shown that ensifentrine was able to achieve a change from baseline in average FEV1 AUC 0-12 hours post dose at week 14 of 94 mL. This was statistically significant compared to placebo with a p-value of p<0.0001. Another solid finding was that patients who received ensifentrine achieved a 42% reduction in the rate of moderate to severe COPD exacerbations over a 24-week period. "Exacerbations" means worsening of COPD symptoms or in other words getting much worse in disease. With ENHANCE-2 meeting the primary endpoint, the wait and see moment now is if the other late-stage study ENHANCE-1 can also meet the very same primary endpoint for COPD patients. Results from this other phase 3 study are going to be released by the end of 2022. This is all great so far, but there is one stipulation which must first be achieved before the company can move on towards potential filing of a regulatory application. It goes to the upcoming data readout by the end of 2022 from ENHANCE-1. This second phase 3 study must also meet the very same primary endpoint. If it does, then Verona will be able to file a New Drug Application to the FDA for the potential approval of ensifentrine for COPD by the 1st half of 2023. However, if this other study doesn't achieve the primary endpoint, then advancement will be up in the air. What do I mean by that? Well, the FDA may require an additional successful study or by a small percentage chance the drug may still be approved. There are opportunities for expansion though. One such opportunity is being able to get ensifentrine to market in China. That's because Verona Pharma made a licensing deal whereby Nuance Pharma could develop and commercialize ensifentrine as a maintenance treatment for COPD in Greater China. These territories include mainland China, Taiwan, Hong Kong and Macau. This was a $219 million strategic collaboration that was done back in June of 2021. Verona received an upfront payment of $40 million and has the potential to earn $179 million in possible clinical, regulatory and commercial milestone payment. Not only that, but it could earn up to double-digit royalties on net sales for products sold in China as well. About a month ago, Nuance Pharma got clearance to initiate both phase 1 and phase 3 studies with ensifentrine for COPD in China. Successful outcomes from both of these studies in that region would mean the possibly to expand the market opportunity for this treatment. Another expansion opportunity would be the potential for ensifentrine to be used for the treatment of patients with Cystic Fibrosis (CF). As I stated above, this drug has a profound effect on being able to activate CFTR, which is important for reducing mucous viscosity in patients with CF. Having said that, this is another avenue for which Verona Pharma can explore to expand the potential opportunity it has with ensifentrine. Financials According to the 10-Q SEC Filing, Verona Pharma had $111 million cash as of June 30, 2022. Throughout the years it has been enacting several measures to raise cash. In March of 2021, it entered into an open market sale agreement with Jefferies LLC to sell shares of our ordinary shares, in the form of ADSs, with aggregate sales noted up to $100 million. Such shares under this agreement could be sold from time to time through the "at the market" equity offering program. During the 6 months ending June 30, 2022 it sold about 80,696 shares under this ATM Program (translates to 10,087 ADSs). It raised approximately $0.1 million after deducting expenses. If it has a need to do so, it still can sell $99.2 million worth of ordinary shares (As ADSs) under this ATM Program. In November 2020, it entered into a loan facility agreement with Silicon Valley Bank of up to $30 million. At the time of closing it got a term loan advance of $5 million. There is an aggregate amount of $10 million available to certain conditions and milestones and then a term loan advance of $15 million subject to clinical developments and other specified conditions. It believed that it would have enough cash to fund its operations until the end of 2023. However, it chose not to do so. As such, the very same day it announced its earnings update, it also disclosed an upsized public offering. It sold a total of 12,400,000 American Depositary Shares ("ADSs") each consisting of 8 ordinary shares of Verona Pharma. In total, it raised an aggregate amount of gross proceeds of $130.2 million before deducting expenses. With this cash raise done just recently, it has now extended its cash runway to mid-2024. Although, my guess is that it may choose to raise cash again at the end of 2023 before it runs out in mid-2024. Risks To Business There are several risks investors should be aware of before investing into this name. The first risk deals with the ENHANCE program. Even though the ENHANCE-2 study met the primary endpoint, using nebulized ensifentrine for the maintenance treatment of patients with COPD, that doesn't mean that the ENHANCE-1 study will also meet on the primary endpoint. Even if this second phase 3 study is successful, the NDA filing must still be accepted by the FDA itself in the 1st half of 2023. Plus, the FDA will have to then review and approve ensifentrine for marketing in the United States.Seeking Alpha • Aug 19
Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Verona Pharma's (NASDAQ:VRNA) (OTC:VNAPF) development partner Nuance Pharma's application seeking to start phase 1 and phase 3 studies of ensifentrine for lung disease in Mainland China received clearance from the Center of Drug Evaluation (CDE). Nuance had filed investigational new drug (IND) to conduct both studies of ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). "This is an important milestone and, based on our recent positive Phase 3 results from our ENHANCE-2 trial in COPD, we remain confident about the potential of ensifentrine to address the urgent global need for a novel treatment for COPD," said Verona President and CEO David Zaccardelli. In 2021 Verona granted Nuance exclusive rights to develop and commercialize ensifentrine in Greater China in a deal worth up to $219M. Verona had received $25M cash upfront and an equity interest worth $15M in Nuance Biotech, the parent company of Nuance Pharma. Verona is also eligible for royalties. VRNA +4.45% to $13.39 premarket Aug. 19Seeking Alpha • Aug 09
Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Verona Pharma press release (NASDAQ:VRNA): Q2 GAAP EPS of -$0.04 beats by $0.23. Cash and cash equivalents at June 30, 2022, were $111.5M (March 31, 2022: $132.8M). The company believes cash and cash equivalents at June 30, 2022, expected cash receipts from the U.K. tax credit program and funding expected to become available under the $30.0M debt facility, will enable Verona Pharma to fund planned operating expenses and capital expenditure requirements through at least the end of 2023.Seeking Alpha • Feb 04
Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
The company’s lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease. The stock is trading at a 75% discount to its high after successful Phase 2b data for Ensifentrine as a maintenance treatment for chronic obstructive respiratory disease. The stock is at a good buy level here ahead of Phase 3 ENHANCE trials data in Q3 and Q4 this year.決済の安定と成長
配当データの取得
安定した配当: VRNAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: VRNAの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Verona Pharma 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (VRNA) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Pharmaceuticals) | 2.1% |
| アナリスト予想 (VRNA) (最長3年) | n/a |
注目すべき配当: VRNAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: VRNAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: VRNAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: VRNAが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2025/10/06 13:28 |
| 終値 | 2025/10/06 00:00 |
| 収益 | 2025/06/30 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Verona Pharma plc 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Patrick Trucchio | Berenberg |
| Cosmin Filker | GBC AG |
| Martin Hall | Hardman & Co. |